A clinical trial to study the effects of two drugs, eberconazole and sertaconazole in patients with localized fungal infection

Efficacy and Safety of Eberconazole vs Sertaconazole in localised tinea corporis ; A randomized control trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/08/009435

Enrollment

150

Registered

2017-08-21

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- localised tinea infections Health Condition 2: L088- Other specified local infections of the skin and subcutaneous tissue

Interventions

Intervention1: Sertaconazole: 2 % cream topically twice daily for 4 weeks Control Intervention1: Eberconazole: 1 % cream topically twice daily for 4 weeks

Eligibility

Inclusion criteria

Inclusion criteria: All patients above the 18years, with clinical diagnosis and mycological confirmation (positive KOH test) for tineawill be included in the study

Exclusion criteria

Exclusion criteria: Patients with tinea of nail Patients who had received any form of treatment for the same prior to the initiation of the study Patients with history of hypersensitivity to study drugs Immunocompromised status Pregnant or lactating women

Design outcomes

Secondary

Measure	Time frame
monitoring adverse eventsTimepoint: throughout study	—

Primary

Measure	Time frame
Improvement in lesion (erythema scaling induration) graded as 0(nil)1(mild)2(moderate)3(severe)Timepoint: Improvement in lesion (erythema scaling induration) graded as 0(nil)1(mild)2(moderate)3(severe) at 2 and 4 weeks	—

Countries

India

Contacts

Public ContactDr Mirunalini R

Mahatma Gandhi Medical college Research Institute

mirunalini3012@gmail.com9894516090

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026